Seroconversion, prior infection may reduce breakthrough COVID-19 risk in people with IMIDs - medwireNews

People on immunomodulatory therapy have similar rates of breakthrough SARS-CoV-2 infection to healthy controls, with a reduced risk seen in those with prior infection or seroconversion after vaccination, research suggests.

medwireNews: People on immunomodulatory therapy have similar rates of breakthrough SARS-CoV-2 infection to healthy controls, with a reduced risk seen in those with prior infection or seroconversion a… [+2204 chars]

full article...